COMPANY PROFILE

Forus Therapeutics

Explore full profile

Advancing novel medicines for hematologic malignancies and other cancers with a focus on Canadian innovations

CanadaFounded 2020Biotech & Life Sciences

Valuation $25–50M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Forus Therapeutics

Forus Therapeutics is a Canadian biopharmaceutical company specializing in the development and commercialization of innovative medicines for hematologic malignancies and other forms of cancer. The company primarily serves patients in Canada but also aims to expand its reach globally. Forus operates in the life sciences sector, focusing on bringing global patient-ready products to Canadians and forming partnerships with early-stage Canadian health innovators. The business model revolves around securing exclusive distribution agreements and developing a robust pipeline of therapeutic assets. Forus generates revenue through the commercialization of FDA-approved cancer medicines and other innovative products. The company has a proven track record, with its leadership team having achieved multiple Health Canada approvals and delivering significant financial returns.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2020
Headquarters: Canada
Employees: 18
Open positions: None listed
Dealroom signal: 45.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Jun 2026	$37M	$37M	PharmaEssentia	↗
EARLY VCEquity / VC	Jan 2021	$20M	$80M	AdMare BioInnovations	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Forus Therapeutics website traffic

Latest recorded traffic for Forus Therapeutics is 4.2K monthly website visits, up 133.3% over the last three months. Forus Therapeutics's team grew 0% over the past year.

Latest monthly visits4.2K 3-month web change+133.3% 1-year team growth0%

Monthly website visitsSep 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
ATAchilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells	Stevenage, United Kingdom	Closed